Optimising Pharmaceutical Production Using Digital Models

The development of safe and effective medicines that meet strict regulatory requirements has traditionally involved extensive experimentation, which can be laborious and costly. Incorporating digital processes, which can be used to produce individual pharmaceutical components, may provide a solution to manufacturing challenges by reducing development time, resource requirements, and costs. The Future Continuous Manufacturing and Advanced Crystallisation Hub, a flagship project at CMAC, at the University of Strathclyde, along with collaborators throughout the UK, has investigated the feasibility of using digital models to reduce costs, time and waste for high quality pharmaceutical production.